Article

Fluoroquinolone helps combat keratitis after lamellar keratectomy

Fort Lauderdale, FL-In a comparison study of three fluoroquinolones, gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan), a new fourth-generation compound, was the most effective agent in the treatment of Mycobacterium chelonae keratitis after lamellar keratectomy in an animal model.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Related Content
Nanoscope Therapeutics forms Vision Advisory Committee
June 30th 2025

Nanoscope Therapeutics forms Vision Advisory Committee

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Q&A: Sevgi Gurkan, MD, on the PER-001 for glaucoma and DME
June 28th 2025

Q&A: Sevgi Gurkan, MD, on the PER-001 for glaucoma and DME

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Iridex enrolls first patient in study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy for DME
June 28th 2025

Iridex enrolls first patient in study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy for DME

Retinal Degeneration Fund providing funding to Opus Genetics to support OPGx-MERTK program
June 28th 2025

Retinal Degeneration Fund providing funding to Opus Genetics to support OPGx-MERTK program

© 2025 MJH Life Sciences

All rights reserved.